Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05106101 · ClinicalTrials.gov registry record · Phase 1
L-glutamine Treatment in Patients With Diverticulosis
A Phase 1 study of Diverticulosis, Colonic, sponsored by Emmaus Medical.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 3
- Study locations
NCT05106101 is a Phase 1 study of Diverticulosis, Colonic that has completed, run by Emmaus Medical. The registered enrollment target is 9 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT05106101, a Phase 1 study of Diverticulosis, Colonic, has completed, sponsored by Emmaus Medical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of the study is evaluate the safety and efficacy of L-glutamine as a treatment for patients with diverticulosis.
Conditions Studied
Interventions
- DRUG L-glutamine
Study Locations (3)
California
- The Lundquist Institute at Harbor-UCLA Medical Center - Torrance
- Ventura Clinical Trials - Ventura
Texas
- Clinical Trials of Texas, Inc. - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-07-19 |
| Est. Completion | 2022-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05106101
The ClinicalTrials.gov registry entry for NCT05106101 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emmaus Medical, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diverticulosis, Colonic appearing as the primary indexed condition, and to 1 intervention - of which L-glutamine is the first listed.
NCT05106101 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.
Frequently Asked Questions
What is clinical trial NCT05106101 about?
NCT05106101 is a clinical study titled "L-glutamine Treatment in Patients With Diverticulosis". The purpose of the study is evaluate the safety and efficacy of L-glutamine as a treatment for patients with diverticulosis.
What is the current status of trial NCT05106101?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2019-07-19. Estimated completion is 2022-12-30.
What conditions does trial NCT05106101 study?
This clinical trial studies the following conditions: Diverticulosis, Colonic.
What interventions are being tested in trial NCT05106101?
The interventions under investigation include: L-glutamine (DRUG).
Who is sponsoring clinical trial NCT05106101?
This trial is sponsored by Emmaus Medical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05106101 being conducted?
This trial has 3 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.